

# Preclinical Study for the Esophageal Cancer Treatment Technology Using the Mechanism of Cancer Cell-Selective Photodynamic Therapy with Next-Generation Photosensitizer HL270

HANLIM PHARM.CO.,LTD



ONCOLOGY	Preclinical
Product Type	Small molecule
Indication	Esophageal cancer
Target	Photodynamic therapy
MoA(Mechanism of Action)	Upon irradiation with a specific wavelength of light, HL270 accumulated in the tumor generates reactive oxygen species (ROS), leading to the destruction of tumor cells.
Competitiveness	<ul style="list-style-type: none"> <li>• High tumor selectivity with minimal normal-tissue retention, enabled by a tumor-specific targeting motif.</li> <li>• Superior ROS generation upon light activation versus comparator photosensitizers.</li> <li>• Faster systemic clearance with lower phototoxicity risk than competing agents.</li> <li>• Consistent tumor targeting and signal across diverse models beyond esophageal cancer, supporting indication-expansion potential.</li> </ul>
Development Stage	Preclinical
Route of Administration	Intravenous administration

*Any unauthorized distribution or reproduction of this material is strictly prohibited.*